Sinocro Medical and Tianjin CanSino Biotechnology Named Most Promising Companies at the ChinaBio Investor Forum

During the 7th ChinaBio® Investor Forum, held December 2-3, 2009 in Tianjin, two young China life science companies have been awarded the “Most Promising Company” prize.
Sinocro Medical of Tianjin won the prize in the Medical Device category, and Tianjin CanSino Biotechnology, a vaccine company, was the winner in the Biopharma group.
Sinocro Medical Inc., which engages in global product licensing, manufacture, and distribution, provides product redesign, upgrades and manufacturing processing development.
Tianjin CanSino Biotechnology Inc., which was formed in January 2009 by scientists with international vaccine experience, aims to develop leading-edge, high quality, high value vaccines for China and other emerging markets at an affordable cost.
Organized by ChinaBio® Accelerator, the Investor Forum was hosted by the Tianjin International Joint Academy of Biotechnology and Medicine (TJAB).
For seventeen young and mid-life companies, the Investor Forum represented an opportunity to present their business plans to venture capitalists who are actively investing in China life sciences.
The VCs and investment bankers in attendance included The Balloch Group, Mingly China Growth Fund, DSM Venturing, Morningside, Fidelity Asia Ventures, DFJ Dragon Fund China, Capital First Partners, IDG Ventures, Suma Ventures, TEDA Venture Capital, Trout Capital, and others.  

Join the discussion